Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography.

Sanders MF, van Doormaal PJ, Beeftink MM, Bots ML, Fadl Elmula FE, Habets J, Hammer F, Hoffmann P, Jacobs L, Mark PB, Persu A, Renkin J, Roditi G, Spiering W, Staessen JA, Taylor AH, Verloop WL, Vink EE, Vonken EJ, Voskuil M, Leiner T, Blankestijn PJ; European Network COordinating research on Renal Denervation (ENCOReD) Consortium..

Eur Radiol. 2017 Mar 7. doi: 10.1007/s00330-017-4770-7. [Epub ahead of print]

PMID:
28271154
2.

Renal denervation in hypertensive patients not on blood pressure lowering drugs.

De Jager RL, Sanders MF, Bots ML, Lobo MD, Ewen S, Beeftink MM, Böhm M, Daemen J, Dörr O, Hering D, Mahfoud F, Nef H, Ott C, Saxena M, Schmieder RE, Schlaich MP, Spiering W, Tonino PA, Verloop WL, Vink EE, Vonken EJ, Voskuil M, Worthley SG, Blankestijn PJ.

Clin Res Cardiol. 2016 Sep;105(9):755-62. doi: 10.1007/s00392-016-0984-y. Epub 2016 Apr 22.

3.

Impact of Adenovirus E4-ORF3 Oligomerization and Protein Localization on Cellular Gene Expression.

Vink EI, Zheng Y, Yeasmin R, Stamminger T, Krug LT, Hearing P.

Viruses. 2015 May 13;7(5):2428-49. doi: 10.3390/v7052428.

4.

Denervation of the renal arteries in metabolic syndrome: the DREAMS-study.

Verloop WL, Spiering W, Vink EE, Beeftink MM, Blankestijn PJ, Doevendans PA, Voskuil M.

Hypertension. 2015 Apr;65(4):751-7. doi: 10.1161/HYPERTENSIONAHA.114.04798. Epub 2015 Feb 2.

5.

The effect of renal denervation on kidney oxygenation as determined by BOLD MRI in patients with hypertension.

Vink EE, Boer A, Verloop WL, Spiering W, Voskuil M, Vonken E, Hoogduin JM, Leiner T, Bots ML, Blankestijn PJ.

Eur Radiol. 2015 Jul;25(7):1984-92. doi: 10.1007/s00330-014-3583-1. Epub 2015 Jan 18.

PMID:
25595641
6.

Renal BOLD-MRI relates to kidney function and activity of the renin-angiotensin-aldosterone system in hypertensive patients.

Vink EE, de Boer A, Hoogduin HJ, Voskuil M, Leiner T, Bots ML, Joles JA, Blankestijn PJ.

J Hypertens. 2015 Mar;33(3):597-603; discussion 603-4. doi: 10.1097/HJH.0000000000000436.

PMID:
25479032
7.

Effects of renal denervation on end organ damage in hypertensive patients.

Verloop WL, Vink EE, Spiering W, Blankestijn PJ, Doevendans PA, Bots ML, Vonken EJ, Voskuil M, Leiner T.

Eur J Prev Cardiol. 2015 May;22(5):558-67. doi: 10.1177/2047487314556003. Epub 2014 Oct 17.

PMID:
25326543
8.

Comparison of the molecular topologies of stress-activated transcription factors HSF1, AP-1, NRF2, and NF-κB in their induction kinetics of HMOX1.

Pronk TE, van der Veen JW, Vandebriel RJ, van Loveren H, de Vink EP, Pennings JL.

Biosystems. 2014 Oct;124:75-85. doi: 10.1016/j.biosystems.2014.09.005. Epub 2014 Sep 6.

PMID:
25199502
9.

The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients.

Vink EE, Verloop WL, Siddiqi L, van Schelven LJ, Liam Oey P, Blankestijn PJ.

Int J Cardiol. 2014 Sep;176(1):8-12. doi: 10.1016/j.ijcard.2014.06.021. Epub 2014 Jun 28.

PMID:
25027168
10.

The blood pressure-lowering effect of renal denervation is inversely related to kidney function.

Vink EE, Verloop WL, Bost RB, Voskuil M, Spiering W, Vonken EJ, Bots ML, Blankestijn PJ.

J Hypertens. 2014 Oct;32(10):2045-53; discussion 2053. doi: 10.1097/HJH.0000000000000282.

PMID:
25023158
11.

Renal denervation in multiple renal arteries.

Verloop WL, Vink EE, Spiering W, Blankestijn PJ, Doevendans PA, Bots ML, Vonken EJ, Voskuil M.

Eur J Clin Invest. 2014 Aug;44(8):728-35. doi: 10.1111/eci.12289.

PMID:
24931208
12.

Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study.

Vink EE, Goldschmeding R, Vink A, Weggemans C, Bleijs RL, Blankestijn PJ.

Nephrol Dial Transplant. 2014 Aug;29(8):1608-10. doi: 10.1093/ndt/gfu192. Epub 2014 May 29.

PMID:
24875664
13.

Eligibility for renal denervation: experience at 11 European expert centers.

Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino F, Wuerzner G, Taylor A, Pechère-Bertschi A, Jokhaji F, Fadl Elmula FE, Rosa J, Czarnecka D, Ehret G, Kahan T, Renkin J, Widimsky J Jr, Jacobs L, Spiering W, Burnier M, Mark PB, Menne J, Olsen MH, Blankestijn PJ, Kjeldsen S, Bots ML, Staessen JA; European Network Coordinating research on REnal Denervation Consortium..

Hypertension. 2014 Jun;63(6):1319-25. doi: 10.1161/HYPERTENSIONAHA.114.03194. Epub 2014 Mar 24.

14.

The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial.

Vink EE, de Beus E, de Jager RL, Voskuil M, Spiering W, Vonken EJ, de Wit GA, Roes KC, Bots ML, Blankestijn PJ.

Am Heart J. 2014 Mar;167(3):308-314.e3. doi: 10.1016/j.ahj.2013.11.010. Epub 2013 Dec 4.

PMID:
24576513
15.

Stabilization of hypoxia inducible factor-1α ameliorates acute renal neurogenic hypertension.

Koeners MP, Vink EE, Kuijper A, Gadellaa N, Rosenberger C, Mathia S, van den Meiracker AH, Garrelds IM, Blankestijn PJ, Joles JA.

J Hypertens. 2014 Mar;32(3):587-97. doi: 10.1097/HJH.0000000000000060.

PMID:
24309492
16.

Eligibility for percutaneous renal denervation: the importance of a systematic screening.

Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML, Doevendans PA, Blankestijn PJ, Spiering W.

J Hypertens. 2013 Aug;31(8):1662-8. doi: 10.1097/HJH.0b013e328362152e.

PMID:
23743806
17.

Renal denervation as therapy for hypertension: potentials and unanswered questions.

Vink EE, Bots ML, Blankestijn PJ.

Eur J Prev Cardiol. 2013 Dec;20(6):980-91. doi: 10.1177/2047487312473019. Epub 2012 Dec 19. Review.

PMID:
23610453
18.

Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.

Vink EE, de Jager RL, Blankestijn PJ.

Curr Hypertens Rep. 2013 Apr;15(2):95-101. doi: 10.1007/s11906-013-0328-5. Review.

PMID:
23354877
19.

Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients.

Vink EE, Blankestijn PJ.

Hypertension. 2013 Feb;61(2):e8. doi: 10.1161/HYPERTENSIONAHA.111.00477. Epub 2012 Dec 3. No abstract available.

20.

Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity.

Vink EE, Blankestijn PJ.

Front Physiol. 2012 Feb 20;3:29. doi: 10.3389/fphys.2012.00029. eCollection 2012.

Supplemental Content

Support Center